Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets.
Lung tissue deposition and antibacterial efficiency of nebulized and intravenous amikacin (AMK) were compared in anesthetized and ventilated piglets suffering from a bronchopneumonia produced by the intrabronchial inoculation of Escherichia coli. AMK was administered 24 hours after the inoculation either through an ultrasonic nebulizer (45 mg x kg-1, n = 10) or by intravenous infusion (15 mg x kg-1, n = 8). Piglets were killed 1 hour after a second AMK administration performed 24 hours after the first one, and lung tissue concentrations of AMK and lung bacterial burden were assessed on multiple lung specimens. The amount of nebulized AMK reaching the tracheobronchial tree represented 38 +/- 6% of the initial nebulizer AMK charge. After nebulization, AMK lung tissue concentrations were 3- to 30-fold higher than after intravenous administration and were influenced by the severity of lung lesions: 188 +/- 175 microg x g-1 in lung segments with mild bronchopneumonia versus 40 +/- 65 microg x g-1 in lung segments with severe bronchopneumonia (p < 0.01). Lung bacterial burden was significantly lower in the aerosol group than in the intravenous group (median = 0 colony forming units. g-1 versus median = 5 x 10(2) colony forming units x g-1, p < 0.001). In conclusion, the deposition of AMK in infected lung parenchyma and the efficiency of bacterial killing were greater after nebulization than after intravenous administration.
Goldstein
Ivan
I
Réanimation Chirurgicale Pierre Viars, Department of Anesthesiology, Pitié-Salpêtrière Hospital, University of Paris VI, Paris, France.
Wallet
Frederic
F
Nicolas-Robin
Armelle
A
Ferrari
Fabio
F
Marquette
Charles-Hugo
CH
Rouby
Jean-Jacques
JJ
D000280:Administration, Inhalation; D000583:Amikacin / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001996:Bronchopneumonia / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology*; D007275:Injections, Intravenous; D008168:Lung / Q000187:drug effects* / Q000382:microbiology / Q000473:pathology; D009330:Nebulizers and Vaporizers; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology*; D012121:Respiration, Artificial; D012720:Severity of Illness Index; D013552:Swine; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000583:Amikacin